Ocugen Provides Business Update with First Quarter 2025 Financial Results
May 9, 2025
Biotechnology
-
-
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
May 7, 2025
-
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
May 7, 2025
-
Pacaso — The $1.3 Trillion Secret That Everyday Investors Are Finally Invited To
May 6, 2025
-
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
April 24, 2025
-
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
April 23, 2025
-
OS Therapies FDA Meeting Request Granted
April 22, 2025
-
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
April 21, 2025
-
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
April 16, 2025
-
PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company
April 16, 2025
-
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom(TM) Manufacturing for Commercial Readiness
April 14, 2025
-
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
April 14, 2025
-
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
April 10, 2025
-
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
April 8, 2025
-
Renovaro Provides Update to Definitive Agreement with Predictive Oncology
April 4, 2025
-
Nutriband Signs Partnership Agreement with Charlotte FC
April 4, 2025